세계의 간질 치료제 시장 규모, 점유율, 동향 분석 : 치료법별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

간질 치료제 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 간질 치료제 시장 규모는 2025년부터 2030년까지 5.7%의 CAGR로 확대되어 2030년에는 154억 7,000만 달러에 달할 것으로 추정됩니다. 간질 발작 치료에 효과적인 신약 개발에 대한 정부 자금의 증가는 간질 치료제 시장 성장에 큰 영향을 미치는 촉진요인입니다. 미국간질협회(AES)는 미국신경학회(American Academy of Neurology), 간질재단(Epilepsy Foundation), 잔디재단(Grass Foundation) 등 다른 단체와 협력하여 연구 개발 활동에 자금을 지원하고, 다양한 프로그램을 통해 의사들에게 치료 라인에 대한 인식 교육을 제공하고 있습니다.

또한, Epilepsy Foundation, American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, Anita Kaufmann Foundation 등의 단체가 시행하는 다양한 인식개선 프로그램은 진단율과 치료율을 더욱 가속화하고 있습니다. 이는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

간질 치료제 시장 : 분석 개요

• 2세대 항경련제는 두 번째로 빠르게 성장할 것으로 예상됩니다. 이 부문에는 Lamotrigine(Lamictal), Levetiracetam(Keppra), Brivaracetam(Briviact), Perampanel(Fycompa) 등이 포함됩니다.
• 3세대 항경련제 부문은 2024년 약 39.7%의 가장 큰 매출 점유율을 차지했습니다. 이 분야의 주요 성장 요인으로는 작용 기전이 개선되고 부작용이 적은 효능이 높은 약물의 출시와 새로운 파이프라인 약물의 출시 대기 등을 들 수 있습니다.
• 2024년 북미가 약 38.7%로 가장 큰 매출 점유율을 차지했습니다. 이 지역의 높은 간질 유병률과 많은 환자 수가 간질 치료제 시장을 이끄는 주요 요인으로 작용하고 있습니다.
• 아시아태평양의 간질 치료제 시장은 예측 기간 동안 괄목할 만한 CAGR을 기록할 것으로 예상됩니다. 이는 이 지역의 인구가 많고 다양하며, 간질 유병률이 급증하고 있으며, 의료 인프라가 개선되고 있기 때문입니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 간질 치료제 시장 : 변수, 동향, 범위

• 시장 연관 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 간질 치료제 시장 : 치료법별 비즈니스 분석

• 시장 점유율 : 치료법별(2024년·2030년)
• 치료법별 대시보드
• 시장 규모 예측과 동향 분석 : 치료법별(2018-2030년)
• 제1세대 항경련제
• 제2세대 항경련제
• 제3세대 항경련제

제5장 간질 치료제 시장 : 유통 채널별 비즈니스 분석

• 시장 점유율 : 유통 채널별(2024년·2030년)
• 유통 채널별 대시보드
• 시장 규모 예측과 동향 분석 : 유통 채널별(2018-2030년)
• 병원 약국
• 소매 약국
• 기타

제6장 간질 치료제 시장 : 지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2030년)
• 시장 대시보드 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 노르웨이
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 진출 기업 개요
• 기업 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • UCB SA
  • Sanofi
  • Pfizer, Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Eisai Co., Ltd.
  • Abbott Laboratories, Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Sunovion Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Neurelis, Inc.

ksm

영문 목차

영문목차

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is estimated to reach USD 15.47 billion by 2030, expanding at a CAGR of 5.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

• Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
• The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
• North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
• Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Epilepsy Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Epilepsy Drugs Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
• 4.4. First Generation Anti-epileptics
  • 4.4.1. First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
• 4.5. Second Generation Anti-epileptics
  • 4.5.1. Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
• 4.6. Third Generation Anti-epileptics
  • 4.6.1. Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2030
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epilepsy Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.K.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. U.K. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Norway Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. UCB S.A.
    • 7.5.1.1. Participant's Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Sanofi
    • 7.5.2.1. Participant's Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Pfizer, Inc.
    • 7.5.3.1. Participant's Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Otsuka America Pharmaceutical, Inc.
    • 7.5.4.1. Participant's overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Eisai Co., Ltd.
    • 7.5.5.1. Participant's Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Abbott Laboratories, Inc.
    • 7.5.6.1. Participant's Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Novartis AG
    • 7.5.7.1. Participant's Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. GlaxoSmithKline plc
    • 7.5.8.1. Participant's Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Sunovion Pharmaceuticals, Inc.
    • 7.5.9.1. Participant's Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Jazz Pharmaceuticals plc
    • 7.5.10.1. Participant's Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Neurelis, Inc.
    • 7.5.11.1. Participant's Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives

관련자료